Modulation of liver enzymes by an Iranian preparation of Echinacea purpurea

Document Type : Case report


1 Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, 1417614411, Tehran, Iran.

2 Shahid Ramezani Clinic, Behboodi Avenue, Azadi Street, Tehran, Iran.


Hepatitis B, a common infectious disease of liver, is transmitted by blood and body fluids like semen and vaginal fluid that carry hepatitis B virus (HBV).  In chronic infection, medical care is required to decrease possibility of cirrhosis and liver cancer. In the present report, the hepatoprotective effect of an Echinacea purpurea preparation (Echiherb®) has been described in a patient who suffered from HBV infection. The levels of both enzymes of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) decreased to their normal level after 6 weeks of treatment. Therefore, this report may provide a new perspective for protection of liver in patients with HBV infection along with other diseases which damage liver cells using E. purpurea preparations.   


[1] Grimm W, Muller HH. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med. 1999; 106: 138-143.
[2] Patel T, Crouch A, Dowless K, Freier D. Acute effects of oral administration of a glycerol extract of Echinacea purpurea on peritoneal exudate cells in female Swiss mice. Brain Behav Immun. 2008; 22: 39.
[3] Cepae BA. WHO monographs on selected medicinal plants. Geneva: World Health Organization, 1999.
[4] Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt, Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005; 57: 929-954.
[5] Coopstead C. Pathophysiology. Missouri: Saunders, 2010.
[6] Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practice (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54: 1-31.
[7] Hollinger FB, Lau DT. Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin N. 2006; 35: 895-931.
[8] Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007; 147: 58-61.
[9] Gopal DV, Rosen HR. Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med. 2000; 107: 100-102.
[10] Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005.
[11] Miller LG. Selected clinical considerations focusing on known or potential drug-herb interaction. Arch Intern Med. 1998; 158: 2200-2211.     
[12] EBSCO CAM Review, Proposed natural treatments for viral hepatitis; Available from: 2014.   
[13] Rusu MA, Tamas M, Puica C, Roman I, Sabadas M. The hepatoprotective action of ten herbal extracts in CCl4 intoxicated liver. Phytother Res. 2005; 1: 744-749.